What specific clinical manifestations of neurotoxicity are associated with isoniazid?

Clinical manifestations include neuritis, optic neuropathy, and seizures. Initial symptoms of polyneuropathy include paresthesias, neuropathic pain, and decreased tactile and pain sensation in the toes and/or fingers. In advanced stages, hypesthesia spreads in a "stocking and/or glove" distribution, deep sensation is impaired, tendon reflexes are diminished or absent, and flaccid atrophic paresis may develop.

Why does vitamin $B_6$ deficiency develop during isoniazid therapy?

Vitamin $B_6$ deficiency occurs because the drug interferes with pyridoxine metabolism, depleting the body's vitamin $B_6$ pool. Prophylactic administration of pyridoxine is recommended alongside isoniazid to prevent neurotoxicity.

Why are patients given different doses of isoniazid despite having the same body weight?

This is due to genetic polymorphism in drug metabolism. Fast acetylators clear the drug in less than an hour and require higher doses, whereas slow acetylators retain the drug for up to three hours, increasing toxicity risk.

Why are B-complex vitamins included in the isoniazid treatment regimen?

Vitamins $B_1$ (thiamine), $B_6$ (pyridoxine), and glutamic acid are necessary to prevent severe adverse effects. They act as a "pharmacological shield," reducing the neurotoxic effects of the drug.

Can isoniazid be used in patients with epilepsy?

No, epilepsy and a predisposition to seizures are absolute contraindications. The drug possesses neurotoxic properties and can provoke convulsive attacks.

Home › Pharmacology › Isoniazid

Isoniazid

*Isoniazidum*

For medical students2 min readUpdated 2026-10-10

Isoniazid is a first-line antituberculous drug characterized by high selectivity of action. Its therapeutic efficacy is based on the ability to selectively disrupt mycobacterial structures while remaining relatively safe for host cells. The primary reason for this selectivity lies in a specific biochemical target found exclusively in the pathogen.

TargetInhibits mycolic acid synthesis in mycobacterial cell walls

MetabolismAcetylated in the liver with complete loss of pharmacological activity

DistributionFreely crosses the blood-brain barrier (BBB)

ToxicityMay cause neurotoxicity, hepatotoxicity, and hypersensitivity reactions

Selectivity and Mechanism of Action

The high toxicity of isoniazid against Mycobacterium tuberculosis and its low toxicity to the human body are due to fundamental differences in cell structure. The key biochemical target of the drug is the synthesis pathway of mycolic acids, which are vital structural components of the mycobacterial cell wall. Because host cells completely lack mycolic acids, the drug does not disrupt normal host cell metabolism, ensuring high therapeutic selectivity.

Pharmacokinetics and Body Distribution

The drug exhibits excellent pharmacokinetic properties. Administered orally via the gastrointestinal tract, it demonstrates high bioavailability and is rapidly absorbed. Peak plasma concentrations are reached within 1 to 4 hours after administration.

Once in systemic circulation, isoniazid distributes evenly across all tissues and organs. A critical property is its ability to easily cross various histhematic barriers. Notably, it freely crosses the blood-brain barrier (BBB), making it effective for central nervous system infections. Metabolites are excreted primarily by the kidneys.

Metabolism and Genetic Polymorphism

Biotransformation occurs in the liver via acetylation. The resulting acetylated metabolite is pharmacologically inactive.

The rate of drug inactivation depends directly on the patient's genetic profile, specifically the activity of the enzyme N-acetyltransferase. Patients are categorized into two main groups:

Fast acetylators: Elimination half-life is less than 1 hour. Due to rapid drug clearance, higher doses are required to maintain a stable therapeutic blood concentration.
Slow acetylators: Elimination half-life is prolonged to approximately 3 hours. This group faces a significantly higher risk of drug accumulation, leading to increased rates of adverse effects.

Clinical Application and Safety Profile

Isoniazid is used for all forms of tuberculosis. The primary route of administration is oral (per os). However, alternative routes such as intramuscular and intravenous injections, or rectal administration, can be used if necessary.

Adverse effects fall into three major categories: neurotoxicity, hepatotoxicity, and allergic reactions.

To mitigate toxicity and prevent complications (providing "pharmacological cover"), the drug is co-administered with:

Vitamin $B_1$ (thiamine);
Vitamin $B_6$ (pyridoxine);
Glutamic acid.

Strict contraindications include epilepsy and seizure disorders due to the high risk of provoking convulsions. It is also contraindicated in severe hepatic impairment (due to pronounced hepatotoxicity) and renal failure (since excretion is primarily renal).

Related Drugs and Analogues

Chemically, isoniazid is a derivative of isonicotinic acid hydrazide. Related drugs in this pharmacological group include ftivazide, metazide, and opiniazide (also known as soluble saluzid).

In combination therapy for tuberculosis, rifampicin is frequently utilized. It is a semisynthetic macrocyclic antibiotic belonging to the ansamycin group. Unlike isoniazid, which is strictly specific to mycobacteria, rifampicin possesses a broad antimicrobial spectrum.

Mnemonic

To remember the "protective" supplements that reduce isoniazid toxicity, use the rule PTG: Pyridoxine (Vitamin $B_6$), Thiamine (Vitamin $B_1$), Glutamic acid.

Frequently asked questions

What specific clinical manifestations of neurotoxicity are associated with isoniazid?: Clinical manifestations include neuritis, optic neuropathy, and seizures. Initial symptoms of polyneuropathy include paresthesias, neuropathic pain, and decreased tactile and pain sensation in the toes and/or fingers. In advanced stages, hypesthesia spreads in a "stocking and/or glove" distribution, deep sensation is impaired, tendon reflexes are diminished or absent, and flaccid atrophic paresis may develop.
Why does vitamin $B_6$ deficiency develop during isoniazid therapy?: Vitamin $B_6$ deficiency occurs because the drug interferes with pyridoxine metabolism, depleting the body's vitamin $B_6$ pool. Prophylactic administration of pyridoxine is recommended alongside isoniazid to prevent neurotoxicity.
Why are patients given different doses of isoniazid despite having the same body weight?: This is due to genetic polymorphism in drug metabolism. Fast acetylators clear the drug in less than an hour and require higher doses, whereas slow acetylators retain the drug for up to three hours, increasing toxicity risk.
Why are B-complex vitamins included in the isoniazid treatment regimen?: Vitamins $B_1$ (thiamine), $B_6$ (pyridoxine), and glutamic acid are necessary to prevent severe adverse effects. They act as a "pharmacological shield," reducing the neurotoxic effects of the drug.
Can isoniazid be used in patients with epilepsy?: No, epilepsy and a predisposition to seizures are absolute contraindications. The drug possesses neurotoxic properties and can provoke convulsive attacks.

Go deeper

Biochemical basis of the inhibition of mycolic acid synthesis by isoniazid
N-acetyltransferase genetic polymorphism: impact on pharmacokinetics
Mechanisms of hepatotoxicity and neurotoxicity in antituberculous drugs
Comparative profile of isonicotinic acid hydrazide derivatives (ftivazide, metazide)
Differences between narrow-spectrum isoniazid and broad-spectrum antibiotics (rifampicin)